New prognostic markers and potential therapeutic targets in human testicular germ cell tumors

Current Medicinal Chemistry

Volumn 18, Issue 33, 2011, Pages 5033-5040

  Chieffi, P ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Aurora B; Gonocytes; GPR30; HMGA; PATZ1; Seminomas; Teratoma; Testicular cancer; Testicular germ cells tumors; Testis

Indexed keywords

ALPHA FETOPROTEIN; ANGIOGENESIS INHIBITOR; AURORA B KINASE; AURORA KINASE INHIBITOR; BARASERTIB; BEVACIZUMAB; BIOLOGICAL MARKER; CISPLATIN; GSK 1070916; HESPERADIN; LACTATE DEHYDROGENASE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN SERINE THREONINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; TOZASERTIB; TRANSCRIPTION FACTOR SOX17; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ADULTHOOD; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER REGRESSION; CANCER RESISTANCE; CARCINOGENESIS; CHROMOSOME 12; CHROMOSOME ANALYSIS; CLINICAL FEATURE; COLORECTAL CANCER; COMPETITIVE INHIBITION; CYTOKINESIS; DISTANT METASTASIS; DRUG EFFICACY; DRUG STRUCTURE; EMBRYO DEVELOPMENT; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LYMPH NODE METASTASIS; METASTASIS; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; NONHUMAN; PRIMORDIAL GERM CELL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SPERMATOCYTE; SPERMATOGONIUM; TESTIS TERATOMA; YOLK SAC TUMOR;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PROTEIN KINASE INHIBITORS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054855496     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797636054     Document Type: Article

References (83)

1. Chieffi, P. Molecular targets for the treatment of testicular germ cell tumors. Mini Rev. Med. Chem., 2007, 7, 755-759. (Pubitemid 47099175)
2. Chieffi P.; Franco, R.; Portella G. Molecular and cell biology of testicular germ cell tumors. Int. Rev. Cell Mol. Biol., 2009, 278, 277-308.
3. Oosterhuis, J.W.; Looijenga, L.H. Testicular germ-cell tumors in a broader perspective. Nat. Rev. Cancer 2005, 5, 210-222. (Pubitemid 40314952)
4. Chieffi, P. Potential new anticancer molecular targets for the treatment of human testicular seminomas Mini Rev. Med. Chem., 2011, 11, 1075-1081.
5. Chaganti, R.S.; Houldsworth, J. Genetics and biology of adult human male germ cell tumors. Cancer Res. 2000, 60, 1474-1482.
6. Ulbright, T.M. Germ cell neoplasm of the testis. Am. J. Surg. Pathol. 1993, 17, 1075-1091.
7. Pottern, A. Testicular and penile cancer. In: Ernstoff Heaney Peschel. Blackwell Science, Oxford, UK, 1998.
8. Jones, R.H.; Vasey, P.A. Part II: Testicular cancer-management of advanced disease. Lancet Oncol. 2003, 4, 738-747. (Pubitemid 37527209)
9. Shelley, M.D.; Burgon, K.; Mason, M.D. Treatment of testicular germ-cell cancer: A cochrane evidence-based systematic review. Cancer Treat. Rev. 2002, 28, 237-253. (Pubitemid 35439438)
10. Al Ghamdi, A.M.; Jewett, M.A. Stage I nonseminomatous germ cell tumours: The case for management by risk stratification. Can. J. Urol. 2005, 12, 62-65.
11. Classen, J.; Souchon, R.; Hehr, T.; Bamberg, M. Treatment of early stage testicular seminoma. J. Cancer Res. Clin. Oncol. 2001, 127, 475-481. (Pubitemid 32662504)
12. Perrotti, M.; Ankem, M.; Bancilla, A.; deCarvalho, V.; Amenta, P.; Weiss, R. Prospective metastatic risk assignment in clinical stage I nonseminomatous germ cell testis cancer: A single institution pilot study. Urol. Oncol. 2004, 22, 174-177. (Pubitemid 38950620)
13. Porcaro, A.B.; Antoniolli, S.Z.; Maffei, N.; Beltrami, P.; Bassetto, M.A.; Curti, P. Management of testicular seminoma advanced disease: Report on 14 cases and review of the literature. Arch. Ital. Urol. Androl. 2002, 74, 81-85. (Pubitemid 34773910)
14. Skakkebaek, N.E. Possible carcinoma-in-situ of the testis. Lancet 1972, 2, 516-517.
15. Wicha, M.S.; Liu, S.; Dontu, G. Cancer stem cells: An old idea-A paradigm shift. Cancer Res. 2006, 66, 1883-1890.
16. Berthelsen, J.G.; Skakkebaek, N.E.; von der Maase, H.; Sorensen, B.L.; Mogensen, P. Screening for carcinoma in situ of the contralateral testis in patients with germinal testicular cancer. Br. Med. J. 1982, 285, 1683-1686. (Pubitemid 13240484)
17. Nielsen, H.; Nielsen, M.; Skakkebaek, N.E. The fine structure of possible carcinomain- situ in the seminiferous tubules in the testis of four infertile men. Acta Pathol. Microbiol. Scand. A. 1974, 82, 235-248.
18. Skakkebaek, N.E.; Berthelsen, J.G.; Giwercman, A.; Muller, J. Carcinomain- situ of the testis: Possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int. J. Androl. 1987, 10, 19-28. (Pubitemid 17081837)
19. Muller, J.; Skakkebaek, N.E.; Nielsen, O.H.; Graem, N. Cryptorchidism and testis cancer. Atypical infantile germ cells followed by carcinoma in situ and invasive carcinoma in adulthood. Cancer 1984, 54, 629-634. (Pubitemid 14060341)
20. Almstrup, K.; Hoei-Hansen, C.E.; Wirkner, U.; Blake, J.; Schwager, C.; Ansorge, W.; Nielsen J.E.; Skakkebaek, N.E.; Rajpert-De Meyts, E.; Leffers. H. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res. 2004, 64, 4736-4743. (Pubitemid 38924515)
21. Looijenga, L.H. Human testicular (non)seminomatous germ cell tumours: The clinical implications of recent pathobiological insights. J. Pathol. 2009, 218, 146-162.
22. Chaganti, R.S.; Houldsworth, J. Genetics and biology of adult human male germ cell tumors. Cancer Res. 2000, 60, 1474-1482.
23. von Eyben, F.E. Laboratory markers and germ cell tumors. Crit. Rev. Clin. Lab. Sci. 2003, 40, 377-427. (Pubitemid 37204500)
24. Chieffi, P.; Battista, S.; Barchi, M.; Di Agostino, S.; Pierantoni, G.; Fedele, M.; Chiariotti, L.; Tramontano, D.; Fusco, A. HMGA1 and HMGA2 protein expression in mouse spermatogenesis. Oncogene 2002, 21, 3644-3650. (Pubitemid 34587696)
25. Franco, R.; Esposito, F.; Fedele, M.; Liguori, G.; Pierantoni, G.; Botti, G.; Tramontano D.; Fusco A.; Chieffi P. Detection of high mobility group proteins A1 and A2 represents a valid diagnostic marker in post-puberal testicular germ cell tumours. J. Pathol. 2008, 214, 58-64.
26. Fedele, M.; Franco, R.; Salvatore, G.; Baronetto, M.P.; Barbagallo, F.; Pero, R.; Chiariotti L.; Sette C.; Tramontano D.; Chieffi G.; Fusco A.; Chieffi, P. PATZ1 gene has a critical role in the spermatogenesis and testicular tumours. J. Pathol. 2008, 215, 39-47. (Pubitemid 351619874)
27. Esposito, F.; Boscia, F.; Franco, R.; Tornincasa, M.; Fusco, A.; Kitazawa, S.; Looijenga, L.H.; Chieffi, P. Down-regulation of estrogen receptor-β associates with transcriptional coregulator PATZ1 delocalization in human testicular seminomas. J. Pathol. 2011, 224. 110-120.
28. Pero, R.; Lembo, F.; Di Vizio, D.; Boccia, A.; Chieffi, P.; Fedele, N.; Pierantoni, M.; Rossi, P.; Iuliano; R.; Santoro, M.; Viglietto, G.; Bruni, C.B.; Fusco, A.; Chiariotti, L. RNF4 is a growth inhibitor expressed in germ cells and lost in human testicular tumours. Am. J. Pathol. 2001, 159, 1225-1230. (Pubitemid 32947952)
29. Pero, R.; Lembo, F.; Chieffi, P.; Del Pozzo, G.; Fedele, M.; Fusco, A.; Bruni, C.B.; Chiariotti, L. Translational regulation of a novel testis-specific RNF4 transcript. Mol. Reprod. Dev. 2003, 66, 1-7. (Pubitemid 36927780)
30. Chieffi, P.; Troncone, G.; Caleo, A.; Libertini, S.; Linardopoulos, S.; Tramontano, D.; Portella G. Aurora B expression in normal testis and seminomas. J. Endocrinol. 2004, 181, 263-70. (Pubitemid 38744675)
31. Esposito, F.; Libertini, S.; Franco, R.; Abagnale, A.; Marra, L.; Portella, G.; Chieffi P. Aurora B expression in post-puberal testicular germ cell tumours. J. Cell. Physiol. 2009, 221, 435-439.
32. Portella, G.; Passaro, C.; Chieffi, P. Aurora B: A new prognostic marker and therapeutic target in cancer. Curr. Med. Chem. 2011, 18, 482-496.
33. Chieffi, P.; Franco, R.; Fulgione, D.; Staibano S. PCNA in the testis of the frog, Rana esculenta: A molecular marker of the mitotic testicular epithelium proliferation. Gen. Comp. Endocrinol. 2000, 119, 11-16. (Pubitemid 30640229)
34. Barbagallo, F.; Baronetto, M.P.; Franco, R.; Chieffi, P.; Dolci, S.; Fry, A.M.; Geremia R.; Sette, C. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. J. Pathol. 2009, 217, 431-441.
35. de Jong, J.; Stoop, H.; Dohle, G.R.; Bangma, C.H.; Kliffen,M.; van Esser, J.W.; van den Bent M.; Kros, J.M.; Oosterhuis, J.W.; Looijenga, L.H. Diagniostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. J. Pathol. 2005, 206, 242-249. (Pubitemid 40754029)
36. Looijenga, L.H.; Stoop, H.; de Leeuw, H.P.; de Gouveia Brazao, C.A.; Gillis, A.J.; van Roozendaal, K.E.; van Zoelen, E.J.; Weber, R.F.; Wolffenbuttel, K.P.; van Dekken, H.; Honecker, F.; Bokemeyer, C.; Perlman, E.J.; Schneider, D.T.; Kononen, J.; Sauter, G.; Oosterhuis, J,W. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 2003, 63, 2244-2250. (Pubitemid 36538633)
37. Atlasi, Y.; Mowla, S.J.; Ziaee, S.A.; Gokhale, P.J.; Andrews, P.W. OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. Stem Cells 2008, 26, 3068-3074.
38. Ledford, H. Doubts raised over stem-cell marker. Nature (London) 2007, 449, 647.
39. Lengner, C.J.; Camargo, F.D.; Hochedlinger, K.; Welstead, G.G.; Zaidi, S.; Gokhale, S. Oct4 expression is not required for mouse somatic stem cell selfrenewal. Cell Stem Cell 2007, 1, 403-415. (Pubitemid 47506536)
40. Liedtke, S.; Enczmann, J.; Waclawczyk, S.; Wernet, P.; Kogler, G. Oct4 and its pseudogenes confuse stem cell research. Cell Stem Cell 2007, 1, 364-366. (Pubitemid 47506539)
41. de Jong, J.; Looijenga, L.H. Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: History and future. Crit. Rev. Oncog. 2006, 12, 171-203. (Pubitemid 46524130)
42. Avilion, A.A.; Nicolis, S.K.; Pevny, L.H.; Perez, L.; Vivian, N.; Lovell Badge, R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 2003, 17, 126-140. (Pubitemid 36062514)
43. Boiani, M.; Scholer, H.R. Regulatory networks in embryo-derived pluripotent stem cells. Nat. Rev. Mol. Cell Biol. 2005, 6, 872-884. (Pubitemid 41568736)
44. Yamaguchi, S.; Kimura, H.; Tada, M.; Nakatsuji, N.; Tada, T. Nanog expression in mouse germ cell development. Gene Expr. Patterns 2005, 5, 639-646. (Pubitemid 40796609)
45. Yates, A.; Chambers, I., 2005. The homeodomain protein Nanog and pluripotency in mouse embryonic stem cells. Biochem. Soc. Trans. 2005, 33, 1518-1521. (Pubitemid 41779728)
46. Hart, A.H.; Hartley, L.; Parker, K.; Ibrahim, M.; Looijenga, L.H.; Pauchnik, M.; Chow, C.W.; Robb, L. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 2005, 104, 2092-2098. (Pubitemid 41579954)
47. de Jong, J.; Stoop, H.; Gillis, A.J.; van Gurp, R.J.; van de Geijn, G.J.; Boer, M.; Hersmus, R.; Saunders, P.T.; Anderson, R.A.; Oosterhuis, J.W.; Looijenga, L.H. Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. J. Pathol. 2008, 215, 21-30. (Pubitemid 351619872)
48. Korkola, J.E.; Heck, S.; Olshen, A.B.; Reuter, V.E.; Bosl, G.J.; Houldsworth, J.; Chaganti, R.S. In vivo differentiation and genomic evolution in adult male germ cell tumors. Genes Chromosomes Cancer 2008, 47, 43-55. (Pubitemid 350191463)
49. Kim, I.; Saunders, T.L.; Morrison, S.J. Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell 2007, 130, 470-483. (Pubitemid 47208520)
50. Gashaw, I.; Grummer, R.; Klein-Hitpass, L.; Dushaj, O.; Bergmann, M.; Brehm, R.; Grobholz, R.; Kliesch, S.; Neuvians, T.P.; Schmid, K.W.; von Ostau, C.; Winterhager, E. Gene signatures of testicular seminoma with emphasis on expression of ets variant gene 4. Cell. Mol. Life Sci. 2005, 62, 2359-2368. (Pubitemid 41500551)
51. Gashaw, I.; Dushaj, O.; Behr, R.; Biermann, K.; Brehm, R.; Rübben, H.; Grobholz R; Schmid, K.W.; Bergmann, M.; Winterhager, E. Novel germ cell markers characterize testicular seminoma and fetal testis. Mol. Hum. Reprod. 2007, 13, 721-727. (Pubitemid 47543410)
52. Staibano, S.; Franco, R.; Mezza, E.; Chieffi, P.; Sinisi, A.; Pasquali, D.; Errico, M.E.; Nappi, C.; Tremolaterra, F.; Somma, P.; Mansueto, G.; De Rosa G. Oestrogen receptor Beta, PCNA, P53, and DNA ploidy: Are they markers of biological behavior in ovarian granulosa cell tumours? Histopathol. 2003, 43, 254-262. (Pubitemid 37115059)
53. Sinisi, A.A.; Chieffi, P.; Pasquali, D.; Kisslinger, A.; Staibano, S.; Bellastella, A.; Tramontano, D. EPN a novel epithelial cell line derived from human prostate tissue. In vitro Cell. Dev. Biol.- An. 2002, 38, 165-172. (Pubitemid 34507488)
54. Picascia, A.; Stanzione, R.; Chieffi, P.; Kisslinger, A.; Dikic, I.,;Tramontano, D. Pyk2 regulates proliferation and differentiation of prostate cells. Mol.Cell. Endocrinol. 2002, 186, 81-87. (Pubitemid 34189781)
55. Chieffi, P.; Colucci D'Amato, G.L.; Staibano, S.; Franco, R.; Tramontano, D. Estradiol-induced mitogen-activated protein kinase (extracellular signalregulated kinase 1 and 2) activity in the frog (Rana esculenta) testis. J. Endocrinol. 2000, 167, 77-84.
56. Chieffi, P.; Colucci-D'Amato, G.L.; Guarino, F.; Salvatore, G.; Angelini, F. 17β- estradiol induces spermatogonial proliferation through mitogenactivated protein kinase (extracellular signal-regulated kinase 1) activity In the lizard (Podarcis s. sicula). Mol. Reprod. Dev. 2002, 61, 218-225. (Pubitemid 34037476)
57. Franco, R.; Boscia, F.; Gigantino, V.; Marra, L.; Esposito, F.; Ferrara, D.; Pariante, P.; Caraglia, M.; Minucci, S.; Chieffi, P. GPR30 is over-expressed in post puberal testicular germ cell tumors. Cancer Biol. Ther. 2011, 11, 609-613.
58. Vitale, G; Dicitore, A.; Sciortino, G.; Abbruzzese, A.; Persani, L.; Santini, D. Role of GPR30 in testicular germ cell tumors: A potential new anticancer target. Cancer Biol. Ther. 2011, 11, 733-735.
59. Carmena, M.; Earnshaw, W.C.; The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. 2003 4, 842-854. (Pubitemid 37411723)
60. Zhou, H.; Kuang, J.; Zhong, L.; Kuo, W.L.; Gray, J.W.; Sahin, A.; Brinkley, B.R.; Sen, S.. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet., 1998, 20, 189-193. (Pubitemid 28455454)
61. Mayer, F.; Stoop, H.; Sen, S.; Bokemeyer, C.; Oosterhuis, J.W.; Looijenga, L.H.J. Aneuploidy of human testicular germ cell tumors is associated with amplification of centrosomes. Oncogene 2003, 22, 3859-3866. (Pubitemid 36819659)
62. Katayama, H.; Brinkley, W.R.; Sen, S. The Aurora kinases: Role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 2003, 22, 451-464. (Pubitemid 36791899)
63. Krause, D.S.; Van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005, 353, 172-187. (Pubitemid 41058349)
64. Pedersini, R.; Vattemi, E.; Mazzoleni, G.; Graiff, C. Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. Lancet Oncol. 2007, 8, 1039-1040. (Pubitemid 47629899)
65. Kemmer, K.; Corless, C.L.; Fletcher, J.A.; McGreevey, L.; Haley, A.; Griffith, D.; Cummings O.W.; Wait, C.; Town, A.; Heinrich, M.C. KIT mutations are common in testicular seminomas. Am. J. Pathol. 2004, 164, 305-313. (Pubitemid 38364614)
66. Palumbo, C.; van Roozendaal, K.; Gillis, A.J.; van Gurp, R.H.; de Munnik, H.; Oosterhuis, J.W.; van Zoelen, E.J.; Looijenga, L.H. Expression of the PDGF alpha-receptor 1.5 kb transcript, OCT-4, and c-KIT in human normal and malignant tissues Implications for the early diagnosis of testicular germ cell tumours and for our understanding of regulatory mechanisms. J. Pathol. 2002, 196, 467-477. (Pubitemid 34262860)
67. Rapley, E.A.; Hockley, S.; Warren, W.; Johnson, L.; Huddart, R.; Crockford, G.; Forman, D.; Leahy, M.G.; Oliver, D.T.; Tucker, K.; Friedlander, M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Heidenreich A.; Geczi, L.; Bodrogi, I.; Olah, E.; Ormiston, W.J.; Daly, P.A.; Looijenga, L.H.; Guilford, P.; Aass, N.; Fosså, S.D.; Heimdal, K.; Tjulandin, S.A.; Liubchenko, L.; Stoll, H.; Weber, W.; Einhorn, L.; Weber, B.L.; McMaster, M.; Greene, M.H.; Bishop, D.T.; Easton, D.; Stratton, M.R. Somatic mutations of KIT in familial testicular germ cell tumours. Br. J. Cancer 2004, 90, 2397-2401. (Pubitemid 38961906)
68. Shamblott, M.J.; Axelman, J.; Wang, S.; Bugg, E.M.; Littlefield, J.W.; Donovan, P.J.; Blumenthal, P.D.; Huggins, G.R.; Gearhart, J.D. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc. Natl. Acad. Sci. USA 1998, 95, 13726-13731. (Pubitemid 28523040)
69. Manova, K.; Nocka, K.; Besmer, P.; Bachvarova, R.F. Gonadal expression of c-kit encoded at the W locus of the mouse. Development 1990, 110, 1057-1069. (Pubitemid 120009477)
70. Looijenga, L.H.; de Leeuw, H.; van Oorschot, M.; van Gurp, R.J.; Stoop, H.; Gillis, A.J.; et al., Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res. 2003, 63, 7674-7678. (Pubitemid 37466695)
71. Heinrich, M.C.; Blanke, C.D.; Druker, B.J.; Corless, C.L. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KITpositive malignancies. J. Clin. Oncol. 2002, 20, 1692-1703. (Pubitemid 34260552)
72. Madani, A.; Kemmer, K.; Sweeney, C.; Corless, C.; Ulbright, T.; Heinrich, M.; Einhorn, L. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann. Oncol. 2003, 14, 873-880. (Pubitemid 36827203)
73. Folkman, J. New perspectives in clinical oncology from angiogenesis research. Eur. J. Cancer 1996, 32, 2534-2539.
74. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 2004, 25, 581-611. (Pubitemid 39099316)
75. Gasparini, G.; Longo, R.; Toi, M.; Ferrara, N. Angiogenic inhibitors: A new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. 2005, 2, 562-577. (Pubitemid 41721816)
76. Viglietto, G.; Romano, A.; Maglione D.; Rambaldi, M.; Paoletti, I.; Lago, C.T.; Califano, D.; Monaco, C.; Mineo, A.; Santelli, G.; Manzo, G.; Botti G, Chiappetta, G.; Persico, M.G. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 1996, 13, 577-587. (Pubitemid 26283854)
77. Ranieri, G.; Patruno, R.; Ruggirei, E.; Montemurro, S.; Valerio, P.; Ribatti, D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic. Curr. Med. Chem. 2006, 1, 1845-1847.
78. Mego, M.; Recková, M.; Sycova-Mila, Z.; Obertova, J.; Brozmanova, K.; Salek, T.; Mardiak, J. Bevacizumab in a growing teratoma syndrome. Ann Oncol. 2007, 18, 962-963.
79. Zakarija, A.; Soff, G. Update on angiogenesis inhibitors. Curr. Opin. Oncol. 2005, 6, 578-583. (Pubitemid 41566411)
80. Lee, D. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer. Clin. Lung Cancer 2005, 7, 89-91. (Pubitemid 43192123)
81. Pasquali, D.; Rossi, V.; Staibano, S.; De Rosa, G.; Chieffi, P.; Prezioso, D.; Mirone, V.; Mascolo, M.; Tramontano, D.; Bellastella A.; Sinisi, A..A. The endocrine gland derived Vascular Endothelial Growth Factor (EGVEGF)/Prokineticin 1 and 2 and receptor expression in human prostate: Upregulation of EG-VEGF/Prokineticin 1 with malignancy. Endocrinology 2006, 147, 4245-4251. (Pubitemid 44268375)
82. Shibuya, M. Vascular endothelial growth factor (VEGF)-receptor 2: Its biological function, major signalling pathway, and specific ligand VEGF-E. Endothelium 2006, 13, 63-69. (Pubitemid 44173108)
83. Nieder, C.; Wiedenmann, N.; Andratschke, N.; Molls, M. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat. Rev. 2006, 32, 348-364. (Pubitemid 44063875)